Are non-torsadogenic human Ether-à-go-go Related Gene ( hERG ) inhibitors associated with better survival for high hERG-expressing glioblastoma patients?
Our findings suggest that hERG is a potential GBM survival marker, and that already approved drugs with non-torsadogenic hERG inhibitory activity may potentially be re-purposed as adjuvant GBM therapy in high hERG-expressing GBM patients.
TEEPS seems to be a valuable screening and diagnostic method for the determination of recurrence in symptomatic and asymptomatic children who underwent successful RFA.